Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Ruxolitinib, an inhibitor of cytokine-signaling,
is effective in the treatment of patients with Chronic Lymphocytic Leukemia for whom
conventional chemotherapy is either too toxic or ineffective.